HLB co-heads Jin Yang-gon and Kim Tae-han confident on liver cancer drug FDA approval: "Expect approval within this year"
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Co-heads' confidence on approval within the year repeats recent statements; no new decision.